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ABSTRACT  
 
Background: People who inject drugs (PWID) are at the greatest risk of hepatitis C virus (HCV) 
infection, yet are often denied immediate treatment due to fears of on-going risk behaviour. Our 
principal objective was to examine evidence of continued injecting drug use among PWID 
following successful treatment for HCV and attainment of a sustained viral response (SVR).  
Methods: PWID who attained SVR between 1992 and June 2012 were selected from the National 
Scottish Hepatitis C Clinical Database.  Hospitalisation and mortality records were sourced for 
these patients using record linkage techniques.  Our primary outcome variable was any 
hospitalisation or death, which was indicative of injecting drugs post-SVR.  Results: The cohort 
comprised 1170 PWID (mean age at SVR 39.6y; 76% male).  The Kaplan Meier estimate of 
incurring the primary outcome after three years of SVR was 10.59% (95% CI, 8.75 – 12.79) 
After adjusting for confounding, the risk of an injection related hospital episode or death post-
SVR was significantly increased with advancing year of SVR: AHR:1.07 per year (95% CI, 1.01 – 
1.14), having a pre-SVR acute alcohol intoxication-related hospital episode: AHR:1.83 (95% CI, 
1.29 – 2.60), and having a pre-SVR opiate or injection-related hospital episode: AHR:2.59 (95% 
CI, 1.84 – 3.64).   Conclusion: Despite attaining the optimal treatment outcome, these data 
indicate that an increasing significant minority of PWID continue to inject post-SVR at an 
intensity which leads to either hospitalisation or death and increased risk of reinfection.  
 
KEYWORDS: hepatitis C, sustained viral response, people who inject drugs, reinfection, record 
linkage 
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1. INTRODUCTION  
 
 It is well established that people who inject drugs (PWID) are at the greatest risk of 
hepatitis C virus (HCV) infection.  Globally, there are an estimated 16 million PWID who are 
currently injecting (Mathers et al., 2008) and of these, 10 million are estimated to have been 
infected with HCV (Nelson et al., 2011).  Chronic HCV infection is a major cause of liver-related 
morbidity and mortality but can be cleared with antiviral treatment and establishment of 
sustained viral response (SVR).  Currently, there is low initiation of HCV antiviral treatment 
among PWID, which likely relates to concerns of adherence to and reinfection post-treatment 
(Martin et al., 2013; Iversen and Maher 2012). Regardless, recent studies have indicated 
treatment outcomes to be acceptable and risk of HCV reinfection to be relatively low among 
PWID, albeit based on only a few small-scale studies conducted among selected populations in 
clinical and harm reduction settings often with limited follow-up (Aspinall et al., 2013; Arain 
and Robaeys, 2014; Grady et al., 2013).  Modelling work has further demonstrated that treating 
PWID is cost-effective and has the potential to reduce HCV transmission and prevalence in this 
population (Martin et al., 2011a, 2013).  Therefore, recommendations state that treatment is not 
to be withheld from an individual based on injection status alone (EASL, 2015).  
 After being deemed one of the greatest public health challenges of our time, HCV was 
made a priority by the Scottish Government and a comprehensive Action Plan was formulated 
to curb the predominately injecting-related epidemic (Chisholm, 2004; Scottish Government, 
2008).  As a result, the overall number of people initiated on antiviral therapy in Scotland more 
than doubled between 2007 and 2010 with ~1000 now treated per year and the vast majority 
(>80%) of these report having ever injected drugs (HPA, 2013).   
 Given this recent and anticipated future upscale in treatment provision among PWID a 
better understanding is needed of the injecting risk behaviours and potential for reinfection 
post-SVR.  Our principal objective, therefore, was to establish evidence and predictors of 
continued engagement in injection drug use post-SVR using a record-linkage approach involving 
both HCV treatment and injecting-related hospitalisation data for a large nationally 
representative cohort of over 1000 PWID. 
2. METHODS 
2.1 Study Population, data sources, and linkage procedure 
 This paper utilised a retrospective cohort of Scottish PWID derived from the HCV 
Clinical Database using data linked from four additional national databases.  Health Protection 
Scotland (HPS) holds and maintains individual patient data for all HCV diagnosed persons who 
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attended a specialist centre for HCV treatment and management across Scotland, referred to as 
the HCV Clinical Database.  This database includes information on patient demographics, 
virology, treatment episodes, epidemiological exposures, and liver disease investigations. 
Inclusion criteria for the study were a history of injection drug use, SVR attained by June, 2012, 
and sufficient identifiers for record-linkage. To enable further database linkage (described 
below), the HCV Clinical Database was first linked to the Scottish HCV Diagnosis Database, as 
previously described (Innes, et al., 2011); this linkage also allowed for scrutiny of patient record 
accuracy, such that patients were dropped if flaws in treatment records were detected (e.g., 
missing diagnosis dates [n=68] or nonsensical treatment dates [n=95]).  
 Hospital episode data were obtained by sourcing Information Services Division (ISD) 
Scotland’s Scottish Morbidity Records (SMR) 01 and 04, which provide general, non-obstetric 
hospital discharge data and psychiatric hospital admissions data respectively.  Hospital 
episodes are coded using the World Health Organisation’s International Classification of Disease 
(ICD) Ninth Revision for all hospitalisations prior to 1996, and Tenth Revision for 
hospitalisations thereafter.  SMR records include six possible diagnostic fields, all of which were 
included in analysis. 
 Mortality data were obtained through sourcing deaths registrations collated by National 
Records of Scotland.  Date and up to eleven causes of death are recorded for each registered 
death using ICD-9 and ICD-10 codes.   
2.2 Linkage Procedure  
 ISD Scotland annually link the Scottish HCV Diagnosis Database to SMR and deaths data. 
This probabilistic linkage technique is estimated to have a rate of false positives or false 
negatives under 5% (Kendrick and Clarke, 1993); the probabilistic linkage has also been 
previously described (McDonald et al., 2008). 
 Thereafter, this linked dataset, containing SMR/deaths data on all HCV diagnosed 
persons, was transferred to HPS and combined with the Clinical and Diagnosis dataset via the 
HCV Diagnosis Database record number to enable extraction of hospitalisation and mortality 
data for all those who had attended a specialist clinic for HCV.  The final linked dataset included 
all relevant demographic, behavioural, morbidity, and mortality data for 1170 Scottish PWID 
who had received antiviral treatment for HCV and attained SVR in the over 20 year period 
between 1992 and June 2012.   
2.3 Outcome Measures  
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 Our primary outcome was an injection-related hospitalisation (IRH) or death (IRD) post-
SVR.  We defined an injection-related cause based on ICD codes present in the primary or 
supplementary diagnostic position.  Heroin has been and remains the predominant drug 
injected in Scotland (University of the West of Scotland, 2015), therefore the relevant outcome 
codes comprised opiate-related: mental and behavioural disorders due to opiate misuse (ICD-10: 
F11), poisoning due to opium (ICD-9: 965.0; ICD-10: T40.0), poisoning due to heroin (ICD-10: 
T40.1), accidental poisoning due to heroin (ICD-9: E8500; ICD-10: X42.4), accidental poisoning 
due to opium (ICD-10: X42.9), intentional self-poisoning by exposure to opium (ICD-10: X62.9), 
opiate dependence (ICD-9: 3040), non-dependent opiate use (ICD-9: 3055), finding opiates in 
blood (ICD-10: R781), and injection-related as defined in previous literature: endocarditis (ICD-
9: 421.0; ICD-10: I33), deep vein thrombosis (ICD-9: 451, 453 ; ICD-10: I80), cellulitis /abscesses 
(ICD-9: 682; ICD-10: L02, L03) (Lloyd-Smith et al., 2008; Irish et al., 2007).  
2.4 Explanatory variables  
 Behavioural and demographic exposure variables of interest were recorded for each 
patient pre-SVR and were obtained from clinical and SMR records.   
 Behavioural variables included presence of an acute alcohol intoxication-related 
hospital episode, and history of an IRH pre-SVR (using the above listed codes).  Alcohol 
intoxication-related hospital episodes have been previously defined and include hospital 
episodes due to problems related to lifestyle alcohol use (ICD-10: Z72.1), mental and behavioural 
disorders due to use of alcohol (ICD-10: F10), toxic effect of alcohol (ethanol, methanol, 
unspecified) (ICD-9: 980.0, 980.1, 980.9; ICD-10: T51.0, T51.1, T51.9), blood alcohol level 100-
240+/ 100 ml (ICD-9: 790.3; ICD-10: Y90.5 – Y90.9), evidence of alcohol involvement determined 
by level of intent (ICD-10: Y91), finding of alcohol in blood (ICD-10: R78.0), poisoning by and 
exposure to alcohol (ICD-9: E8600-02, E8609; ICD-10: X45, X65, Y15), alcohol deterrents (ICD-
10: Y57.3), alcohol abuse counselling and surveillance (ICD-10: Z71.4), non-dependent alcohol 
abuse (ICD-9: 305.0).  
 Additional explanatory variables for each PWID included age at SVR, gender, year of SVR 
(date of SVR was defined as negative HCV RNA reading 24 weeks post-treatment completion),  
and presence of cirrhosis at treatment initiation.  Age at SVR was categorised into three groups 
(<30, 30-44, ≥45).  Year of SVR was categorised for descriptive analysis (1992-2004, 2005-
2012) and kept continuous for statistical modelling.  Patients who were cirrhotic at time of 
treatment initiation were identified by the Clinical Database based on a combination of (i) 
clinical examination, (ii) radiology (ultrasound, transient elastography, computed tomography, 
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or magnetic resonance imaging), or (iii) liver biopsy, as previously described (Innes, et al., 
2012).  
2.5 Statistical Analyses 
 All statistical analyses, data storage, and manipulation were conducted using STATA 
version 12 (College Station, TX, USA).  
2.5.1 Analysis of first-time opiate or injection related hospital event or death. Firstly, Kaplan Meier 
survival estimates were used to calculate the estimated proportion of the cohort who had a 
primary outcome at three years post-SVR attainment. Secondly, we used multivariate Cox 
regression to determine predictors of time to first IRH or IRD post-SVR.  Time at risk was 
calculated in person years (PY) from date of SVR attainment to first event or end of follow-up 
(30th June 2012).  Adjusted hazard ratios (AHR) post-SVR were generated using a multivariate 
Cox regression analysis including all covariates irrespective of univariate association. 
2.5.2 Analysis of multiple opiate or injection related hospital events and/or death. A multiple 
events Poisson regression model was used to investigate predictors of an IRH and/or IRD risk 
post-SVR.  Time at risk was calculated from date of SVR and stopped at either death of end of 
follow up, but was not censored for periods spent in hospital for any admission type.  Crude, 
unadjusted rates were measured per 100 PY of follow-up.   
3. RESULTS 
3.1 Sample Characteristics (Table 1) 
 Table 1 displays the demographic and behavioural characteristics of the cohort with 
regard to our primary outcome (i.e., an injection-related hospital episode or death post-SVR).  
The average age at SVR was 39.6 years (standard deviation ± 8.2 years; range 19.0-67.7 years), 
and the majority were male (76%).  The majority of the cohort (76%) attained SVR between 
2006- June 2012.  A history of an IRH pre-SVR was found for 427 (37%) of the cohort, of which 
222 had an IRH within three years prior to treatment initiation (relating to 19% of the entire 
cohort). Thirteen percent had at least one opiate or injection-related hospital episode or death 
during an average follow up of 4.1 years post-SVR.  Mental and behavioural disorders due to 
opiate misuse (ICD10: F11) was the predominant discharge diagnosis and cause of death among 149 
Page 7 of 21
Ac
ce
pte
d M
an
us
cri
pt
first-time post-SVR IRH and IRD events, accounting for 61% of our outcome, followed by 
cellulitis/abscess (22%), and opiate dependence (7%). (See Supplementary Table 11) 
  Kaplan Meier estimates of incurring our primary outcome at three years are 
presented in Table 1. Estimates were calculated at three years ensuring that >50% of our cohort 
had at least this amount of follow-up time post-SVR.  The overall estimate of injection-related 
hospitalisation or death at three years post-SVR was 10.59% (95%CI 8.75 – 12.79%).  This 
proportion varied by demographic/behavioural factors and was highest among those with an 
IRH pre-SVR (19.24%, 95%CI 15.2% – 24.2%).  The lowest estimated proportion of an IRH or 
IRD was observed for those who had attained SVR between 1992-2000 (2.22%, 95% CI 0.32 – 
14.75%).  A Kaplan Meier curve of those PWID who remain free of both an IRH and IRD over 8 
years is illustrated in Figure 1.  
3.2 First-time opiate or injection-related hospital episode post-SVR 
 The overall crude rate of our outcome post-SVR was 3.12 per 100 PY (Table 2), with the 
highest incidence rate noted in PWID who had an IRH pre-SVR (6.04 per 100 PY).  Within the 
respective exposure variable groups, those aged 30 or younger at SVR had the highest incidence 
(3.92 per 100 PY) when compared with those aged 45 and older, along with females (3.75 per 
100 PY), and those with an alcohol intoxication-related hospital episode pre-SVR (5.67 per 100 
PY).  
 All covariates, with the exception of gender and cirrhosis, were associated with our 
outcome in univariate analysis (Table 2).  Significant independent predictors of an IRH or IRD 
post-SVR identified in multivariate Cox regression include: year of SVR (AHR: 1.07, 95% CI, 1.01 
– 1.14), history of alcohol intoxication-related hospital episode pre-SVR (AHR: 1.83, 95% CI 1.29 
– 2.60), and history of IRH pre-SVR (AHR: 2.59, 95% CI 1.84 – 3.64).  Age at SVR did not retain 
its significance after adjusting for covariates. 
3.3 Multiple opiate and injection-related hospital episodes post-SVR 
 Among 1170 PWID followed from SVR attainment, we observed a total of 225 injection-
related hospital episodes and 11 deaths due to an injection-related cause.  Thus there were a 
total of 149 first-time admissions/deaths and a further 87 subsequent readmissions/deaths 
following first IRH; the latter 87 readmissions/deaths related to 48 PWID with up to 8 events 
                                                          
1 Supplementary material can be found by accessing the online version of this paper at 
http://dx.doi.org and by entering doi:...  
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observed per PWID (Table 3).  In univariate analysis, all factors with the exception of cirrhosis 
at treatment initiation were associated with incidence of IRH and/or IRD post-SVR.  Female 
gender (adjusted incidence rate ratio [AIRR]: 1.32, 95% CI 1.00 – 1.73), history of alcohol 
intoxication-related hospital episode pre-SVR (AIRR: 2.95, 95% CI 2.24 – 3.89), and history of 
IRH pre-SVR (AIRR: 2.59, 95% CI 1.99 – 3.36) retained their significance in the multivariate 
model.   
4. DISCUSSION 
 
 With highly effective but costly HCV treatments on the horizon and potential demand for 
treatment to increase particularly among the population who injects drugs, it is essential that 
the behaviours which pose a risk of reinfection post-SVR are well understood.  There have been 
few small-scale studies examining engagement in injection drug use post-HCV antiviral 
treatment induced SVR.  These studies rely on participation, accurate self-report by PWID, and 
have varied in respect of recruitment setting; thus, rates of continued injection drug use ranged 
considerably from 33% to 100% post-SVR (Dalgard, 2005; Grebely et al., 2009; Page et al., 
2009).  Results obtained from our study were derived from a large anonymous record-linkage 
exercise of routine administrative data on all PWID undergoing therapy, thereby increasing 
cohort size and avoiding participation bias.   
 This study estimated that 10.6% of the Scottish cohort of 1170 PWID (i.e., those known 
to have acquired their infection through injecting drug use) had been in hospital for or had died 
from an injection-related cause in the first three years post-SVR.  This compared to a greater 
proportion (19%) of the cohort who had an IRH in the three years prior to treatment initiation, 
which is consistent with recent evidence, also from Scotland, suggesting that patients attaining 
SVR lead healthier lives (Innes et al., 2015).  A minority of people who actively inject drugs 
likely end up in hospital or die from an injection-related cause each year.  For example, a survey 
in England recently found 13% of 1058 people who were actively injecting drugs had been 
admitted to hospital with an injection site infection in the last year (Hope et al., 2008).  Further, 
a Canadian study found that approximately 26% of active PWID, recruited through street 
outreach, had been admitted to hospital (for any cause) in the previous six months (Palepu et 
al., 1999).  Given this context, it is then plausible that a greater proportion of our cohort – 
potentially several-fold higher than the 10.6% reported here within three years of SVR – were 
injecting drugs during the early years following successful therapy. 
 A relatively low risk of HCV reinfection post-SVR has so far been reported from studies 
involving PWID (pooled rate of 2 per 100 PY from recent meta-analysis), with risk of HCV 
reinfection greater among those reporting actively injecting drugs (6 per 100PY); however 
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these were predominately centred in settings with considerable harm reduction and clinical 
support and thus may not reflect the wider injecting population (Aspinall et al., 2013).  The 
results here show the risk of an IRH or IRD rose over time with increasing year of SVR 
attainment.  This likely reflects Scotland’s expansion of HCV antiviral treatment among people 
who had ever injected drugs, having increased nine-fold between 2001-2 and 2009-10 
(McDonald et al., 2014), and broadening to not just those who have injected in the distant past, 
but to those who have injected recently and continue to do so.  The expansion of therapy in this 
population group was consistent with the aims of the Scottish Government’s Action Plan on HCV 
and now also the European and Global guidelines which endorse treatment of patients with on-
going drug use.  Thus, our data would suggest that reinfection post-therapy may rise in Scotland, 
and could increase in other countries as therapy is scaled up among PWID populations.  
 Additional analysis considering multiple events per patient yielded similar predictors, 
but also highlighted a significantly increased rate among females versus males.  Female gender 
was an independent predictor of multiple injection-related hospitalisations post-SVR, a finding 
corroborating previous research (Palepu et al., 2011).  It is hypothesized that this significant 
disparity in incidence between males and females could be due to many reasons including 
gender-related differences in care seeking behaviour.   
 Individuals found to have been hospitalised for either an IRH or alcohol intoxication-
related cause prior to antiviral therapy initiation, being 30% of our cohort, were at significantly 
increased risk of both single and multiple IRH and/or IRD post-SVR.  Likewise, those younger 
compared to older in age, although not significant in multivariate analysis, were more likely to 
engage in injecting practices post-successful treatment, as indicated by an estimated 15% and 
7% of those aged under 30 and over 45 years, respectively, having been in hospital or died from 
an injection-related cause within three years of SVR attainment.  This hospitalisation data may 
then help target a group who are particularly prone to re-engaging with risk behaviours.   
 There are some limitations to our study.  Using hospital records will most likely under-
represent injecting frequency post-SVR.  Hospitalisations represent extreme injecting outcomes 
(e.g., poisoning, overdose, severe injury), and thus likely underestimate the extent to which 
PWID are continuing to engage in injecting drugs post-successful treatment.  Additionally, 
utilising hospital records relies on ICD codes as a measure of current-diagnosis.  ICD codes 
indicating opiate use or injection drug use will not always necessarily indicate acute injecting 
episodes and could thus include historical events or non-injecting opiate abuse, both of which 
could have caused an overestimation of the true rate of hospitalisation for post-SVR injection 
drug use.  Our analysis of multiple events did not exclude time spent in hospital and thus that 
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may have weakened the strength of association with some covariates, compared to that 
observed in the primary analysis of first-time IRH or IRD; further follow-up is required to fully 
assess the extent of readmission/death in this cohort. 
 This study did not explore engagement in additional risk factors of HCV reinfection (e.g., 
tattooing, sexual practices) post-SVR, although these are unlikely to pose the same population 
risk as continued injecting drug use.  Further, we did not consider specifically the risk of 
reinfection here, as it required follow-up laboratory data on HCV RNA testing, but this is now 
the focus of a subsequent study.  This risk behaviour research has, however, informed the need 
to fully understand the extent of testing and diagnosis of PWID post-SVR.  Additionally, SVR 
patients account for roughly 60% of the overall treated population, and we the efore did not 
report on the behaviours of remaining 40% who were treated and did not attain the optimal 
outcome, leaving scope for further research using such a comparison group (Innes, et al., 2012).   
4.1 Implications and Recommendations 
 Treatment induced viral clearance is well known to improve health outcomes, yet it 
does not completely remove the risk of liver-related morbidity and mortality.  Lifestyle factors- 
that can either accelerate the rate of liver disease progression (e.g., alcohol consumption) or 
cause re-infection pose a significant excess risk of liver disease among patients who have 
attained SVR (Innes et al., 2013).  This study indicates that the risk of HCV reinfection post-SVR 
might  increase as treatment is expanded and scaled up among injecting populations.   
 
 Treatment regiments that are highly effective, reduced in toxicity, and shorter in 
duration are at the forefront of current HCV research and care.  The benefits of such treatments 
offer greater opportunity to scale up therapy among this population who inject drugs than ever 
before.  Modelling studies have further illustrated the potential to reduce and control HCV 
transmission among PWID through such a treatment-to-prevent approach (Martin et al., 2011b, 
2013).  Our findings highlight that for patients who successfully complete treatment and would 
ordinarily be discharged from care, continued monitoring with RNA testing would be advised 
for those with on-going risk behaviour, in line with European guidelines (EASL, 2015).  Harm 
reduction interventions aimed at reducing the risk of HCV transmission should also continue to 
be promoted once treatment ceases. 
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FIGURE LEGEND 
Figure1. Kaplan Meier Curve estimating the proportion of patients remaining free of an 
injection-related hospitalisation or death among 1170 PWID who attained SVR in Scotland, 
1992-2012. 
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Table 1. Description of cohort of 1170 PWID who attained a sustained viral response (SVR) in 
Scotland, 1992-2012; Kaplan Meier estimates of IRH or IRD at three years post-SVR 
 
Abbreviations; IRH, injection-related hospital episode; IRD, injection-related death; SVR, sustained viral 
response; CI, confidence interval 
Characteristics N(%) IRH or IRD post-SVR, n (%N) Kaplan Meier estimated 
proportions of opiate or 
injection hospital 
episodes/deaths at 3 
years post-SVR % (95% 
CI) 
 
Total 1170 (100)    149  (13) 10.59 (8.75 – 12.79) 
Age at SVR  
<30 
30-44 
  ≥45 
 142 (12) 
738 (63) 
290 (25) 
  23(16) 
103(14) 
23(8) 
13.71 (8.53 – 21.62) 
11.28 (8.93 – 14.21) 
  7.19 (4.50 – 11.39) 
Gender  
    Male 
    Female 
889 (76) 
  281 (24) 
104 (12) 
   45 (16) 
10.26 (8.20 – 12.80) 
11.65 (8.07 – 16.66) 
Year of SVR  
    1992-2000   45   (4)   8  (18) 2.22 (0.32 – 14.75) 
    2001-2005 236 (20)  48 (20) 8.50 (5.57 – 12.86) 
    2006-2012 889 (76)  93 (10) 12.03 (9.67 – 14.93) 
Cirrhosis diagnosis at treatment initiation  
    No 
    Yes 
1081 (92) 
    89   (8) 
137 (13) 
12 (13) 
10.28 (8.40 – 12.56) 
14.65 (8.05 – 25.73) 
Alcohol intoxication-related hospital episode pre-SVR 
    No 
    Yes 
  912 (78) 
  258 (22) 
   98 (11) 
   51 (20) 
8.69 (6.84 – 11.02) 
17.58 (12.81 – 23.87) 
Opiate or injection-related hospital episode pre-SVR  
    No 
    Yes 
  743 (63) 
  427 (37) 
   63  (8) 
   86 (20) 
6.04 (4.38 – 8.31) 
19.24 (15.22 – 24.16) 
Tables 1, 2, 3
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Covariate PY Unadjusted crude rate 
per 100 PY (95% CI) 
IRH or IRD post-SVR 
Univariate 
(HR, 95%CI) 
p-value Multivariate  
(AHR, 95% CI) 
 
p-value 
Study 
Population 
4764 3.12 (2.66 – 3.67)    
Age at SVR   
<30  586 3.92 (2.61 – 5.90) 2.07 (1.17 – 3.66)   0.013 1.51 (0.83 – 2.73)   0.179 
30-44 3023 3.41 (2.81 – 4.13) 1.65 (1.02 – 2.67)   0.041 1.48 (0.93 – 2.35)   0.099 
  ≥45 1155 1.99 (1.32 – 2.99) 1.00 (Baseline)  1.00 (Baseline)  
Gender     
Male  
Female 
   3564 2.92 (2.41 – 3.54) 1.00 (Baseline)  1.00 (Baseline)  
   1200  3.75 (2.89 – 5.02) 1.29 (0.91 – 1.83)   0.155 1.28 (0.90 – 1.83) 0.164 
Year of SVR 1.10 (1.03 – 1.16)   0.006 1.07 (1.01 – 1.14) 0.025 
Cirrhosis diagnosis at time of treatment initiation    
 No   4376 3.09 (1.76 – 5.45)     1.00 (Baseline)  1.00 (Baseline)  
Yes     388 3.13 (2.64 – 3.70) 1.05 (0.58 – 1.90)   0.876 1.03 (0.56-1.89) 0.966 
Alcohol intoxication-related hospital episode pre-SVR    
No   3864 2.54 (2.08 – 3.09) 1.00 (Baseline)  1.00 (Baseline)  
Yes     900 5.67 (4.31 – 7.46) 2.17 (1.54 – 3.05) <0.001 1.83 (1.29 – 2.60) 0.001 
Opiate or injection-related hospital episode pre-SVR  
No   3342 1.88 (1.47 – 2.41) 1.00 (Baseline)  1.00 (Baseline)  
Yes   1422 6.04 (4.90 – 7.47) 3.08 (2.22 – 4.27) <0.001 2.59 (1.84 – 3.64) <0.001 
      
Table 2. Cox regression, risk of first IRH or IRD among 1170 PWID who attained SVR in 
Scotland, 1992-2012. 
Abbreviations; PY, person years; IRH, injection-related hospital episode; IRD, injection-related death, SVR, sustained 
viral response; HR, hazard ratio; AHR, adjusted-hazard ratio; CI, confidence interval 
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Covariate N PY  Unadjusted crude rate 
per 100 PY (95% CI) 
IRH and/or IRD post-SVR 
  Univariate (IRR, 
95%CI) 
p-
value  
Multivariate 
(AIRR, 95%CI) 
p-value  
Study 
Population 
236  5319      4.44 (3.87 – 5.00)   
Age at SVR     
<30   37 771   4.79 (3.25 – 5.35) 1.77 (1.13 – 2.79) 0.012 1.32 (0.83 – 2.09) 0.239 
30-44 160 3456  4.62 (3.91 – 5.35) 1.48 (1.04 – 2.11) 0.027 1.22 (0.85 – 1.74) 0.280 
≥45  39 1092  3.57 (2.45 – 4.69) 1.00 (Baseline)  1.00 (Baseline)  
Gender 
Male 159 3977  4.00 (3.76 – 4.62) 1.00 (Baseline)  1.00 (Baseline)  
Female  77 1342  5.74 (4.45 – 7.02) 1.48 (1.13 – 1.95) 0.005 1.32 (1.00 – 1.73)  0.048 
Year of SVR   1.05 (1.01 – 1.08) 0.015 1.03 (0.99 – 1.07) 0.107 
Cirrhosis diagnosis at treatment initiation 
No 213 4849  4.39 (3.80 – 4.98) 1.00 (Baseline)  1.00 (Baseline)  
Yes   23 470    4.89 (2.89 – 6.89) 1.24 (0.81 – 1.91) 0.327 1.03 (0.66 – 1.60) 0.894 
Alcohol intoxication-related hospital episode pre-SVR 
No 111 4223       2.62 (2.14 – 3.11) 1.00 (Baseline)  1.00 (Baseline)  
Yes 125 1096    11.41 (9.40 – 13.40) 2.85 (2.19 – 3.71) <0.001 2.59 (1.99 – 3.36) <0.001 
Opiate or injection related hospital episode pre-SVR 
No 88 3621  2.43 ( 1.92 – 2.94) 1.00 (Baseline)  1.00 (Baseline)  
Yes 148 1698  8.71 (8.00 – 9.43) 3.79 (2.89 – 4.97) <0.001 2.95 (2.24 – 3.89) <0.001 
Table 3. Poisson regression, incidence and risk of multiple IRH and/or IRD among 1170 
PWID who attained SVR in Scotland, 1992-2012. 
. 
 
N, Number of observed hospital episodes; PY, person years; Rate, fitted number of hospital episodes per 100 
person-years; IRH, injection-related hospital episode; IRD, injection-related death; SVR, sustained viral 
response; IRR, incidence rate ratio; AIRR, adjusted-incidence rate ratio; CI, confidence interval 
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Highlights:  
 We followed-up a nationally representative cohort of 1170 people who inject drugs 
(PWID) who had attained sustained viral response (SVR) 
 Data linkage was used to examine injection-related morbidity/mortality events 
 An increasing minority of our cohort had a post-SVR injection-related event 
 Continued follow-up and promotion of harm reduction is warranted post-SVR in 
PWID 
 The approach adopted here can be used to inform on trends in HCV reinfection risk 
 
